Full-year profit now forecast for Medivir

Full-year profit now forecast for Medivir Medivir is amending its previous break-even forecast for 1999 and now expects to report full-year profit of approximately 20 MSEK in 1999. The reason for the improvement is that progress of the MIV-150 HIV project is exceeding plan, thus resulting in receipt of an additional milestone payment from Chiron Corporation, as well as a strong exchange rate for the US dollar. Huddinge 18 October 1999 Medivir AB (publ) For more information: See also pressrelease regarding Chiron dated 18 October. Jonas Frick, President, Medivir AB, phone no +46-8-608 31 00 Anna Bernsten, Vice President Business Development and Investor Relations, Medivir AB, phone no +46-8-608 31 05, +46-709-369 069 or e-mail: anna.bernsten@medivir.se. For more information about Medivir: www.medivir.se Medivir is a research and development company which develops new and better substances for the treatment of infectious diseases. The subsidiary company CCS AB develops, manufactures and markets body-care products and pharmaceuticals. The Group consists of the parent company, Medivir AB, the CCS AB subsidiary and UK company CCS (UK) Ltd. ------------------------------------------------------------ Please visit http://www.bit.se for further information The following files are available for download: http://www.bit.se/bitonline/1999/10/18/19991018BIT00090/bit0001.doc http://www.bit.se/bitonline/1999/10/18/19991018BIT00090/bit0002.pdf